Abstract:Recent advances in cancer treatment have emerged from new immunotherapies targeting T-cell inhibitory receptors, including cytotoxic T-lymphocyte associated antigen (CTLA)-4 and programmed cell death (PD)-1. In this context, anti-CTLA-4 and anti-PD-1 monoclonal antibodies have demonstrated survival benefits in numerous cancers, including melanoma and non-small-cell lung carcinoma. PD-1-expressing CD8+ T lymphocytes appear to play a major role in the response to these immune checkpoint inhibitors (ICI). Cytotoxic T lymphocytes (CTL) eliminate malignant cells through recognition by the T-cell receptor (TCR) of specific antigenic peptides presented on the surface of cancer cells by major histocompatibility complex class I/beta-2-microglobulin complexes, and through killing of target cells, mainly by releasing the content of secretory lysosomes containing perforin and granzyme B. T-cell adhesion molecules and, in particular, lymphocyte-function-associated antigen-1 and CD103 integrins, and their cognate ligands, respectively, intercellular adhesion molecule 1 and E-cadherin, on target cells, are involved in strengthening the interaction between CTL and tumor cells. Tumor-specific CTL have been isolated from tumor-infiltrating lymphocytes and peripheral blood lymphocytes (PBL) of patients with varied cancers. TCRβ-chain gene usage indicated that CTL identified in vitro selectively expanded in vivo at the tumor site compared to autologous PBL. Moreover, functional studies indicated that these CTL mediate human leukocyte antigen class I-restricted cytotoxic activity toward autologous tumor cells. Several of them recognize truly tumor-specific antigens encoded by mutated genes, also known as neoantigens, which likely play a key role in antitumor CD8 T-cell immunity. Accordingly, it has been shown that the presence of T lymphocytes directed toward tumor neoantigens is associated with patient response to immunotherapies, including ICI, adoptive cell transfer, and dendritic cell-based vaccines. These tumor-specific mutation-derived antigens open up new perspectives for development of effective second-generation therapeutic cancer vaccines.

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

Patient HLA Class I Genotype Influences Cancer Response to Checkpoint Blockade Immunotherapy

Tumor Immune Checkpoints and Their Associated Inhibitors

Immune Checkpoint Blockade Enhances Immune Activity of Therapeutic Lung Cancer Vaccine

Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy

[Immune-checkpoints: the new anti-cancer immunotherapies]

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

Strategies to optimize the promise of checkpoint-targeted anti-cancer therapy

The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets

Immune Checkpoints in Cancers: From Signaling to the Clinic

Immune checkpoint signaling and cancer immunotherapy

Cancer immunotherapy: broadening the scope of targetable tumours

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Active Immunotherapy Combined with Blockade of a Coinhibitory Pathway Achieves Regression of Large Tumor Masses in Cancer-prone Mice

Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer

Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy

Cancer neoantigens as potential targets for immunotherapy

Targeting a neoantigen derived from a common TP53 mutation

Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models

Tumour-intrinsic resistance to immune checkpoint blockade